Who
Michael Secora
CFO & Chief Corp Dev Ofcr
Company insider
Files Form 4 as: CFO & Chief Corp Dev Ofcr, Iambic Therapeutics; Chief Financial Officer, Recursion Pharmaceuticals.
In numbers
- Trades disclosed
- 146
- Buys
- 0
- Sells
- 34
- Bought
- $0
- Sold
- $6.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 20 Apr 2021
- Last trade
- 16 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Oct 2026filed 19 Oct 2026 | IAM Iambic Therapeutics | SEC FORM 4 Code C | —61,342 | filing |
| 16 Oct 2026filed 19 Oct 2026 | IAM Iambic Therapeuticsoption or derivative | SEC FORM 4 Code C | —61,342 at $0.00 | filing |
| 14 Oct 2026filed 16 Oct 2026 | IAM Iambic Therapeutics | SEC FORM 4 Code A | —28,400 at $0.00 | filing |
| 14 Oct 2026filed 16 Oct 2026 | IAM Iambic Therapeuticsoption or derivative | SEC FORM 4 Code A | —170,300 at $0.00 | filing |
| 15 Nov 2024filed 19 Nov 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $74K11,937 at $6.18 | filing |
| 13 Nov 2024filed 14 Nov 2024 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,375 at $0.00 | filing |
| 13 Nov 2024filed 14 Nov 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $87K39,375 at $2.22 | filing |
| 13 Nov 2024filed 14 Nov 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $115K15,000 at $7.66 | filing |
| 12 Nov 2024filed 14 Nov 2024 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,375 at $0.00 | filing |
| 12 Nov 2024filed 14 Nov 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $87K39,375 at $2.22 | filing |
| 12 Nov 2024filed 14 Nov 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $115K15,000 at $7.64 | filing |
| 9 Oct 2024filed 10 Oct 2024 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,375 at $0.00 | filing |
| 9 Oct 2024filed 10 Oct 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $87K39,375 at $2.22 | filing |
| 9 Oct 2024filed 10 Oct 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $95K15,000 at $6.36 | filing |
| 8 Oct 2024filed 10 Oct 2024 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,375 at $0.00 | filing |
| 8 Oct 2024filed 10 Oct 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $87K39,375 at $2.22 | filing |
| 8 Oct 2024filed 10 Oct 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $95K15,000 at $6.32 | filing |
| 11 Sep 2024filed 12 Sep 2024 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,375 at $0.00 | filing |
| 11 Sep 2024filed 12 Sep 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $87K39,375 at $2.22 | filing |
| 11 Sep 2024filed 12 Sep 2024 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $95K15,000 at $6.32 | filing |
News
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Lifted to "Sell" by Wall Street ZenRXRX · dailypolitical.com · 18 Oct 2026Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) and Oramed Pharmaceuticals (NASDAQ:ORMP)RXRX · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Michael Secora; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.